EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Assessment of the molecular mechanisms of drug‐induced hidden cardiotoxicity by a multi‐omics approach: The example of rofecoxib

Bennet Y Weber, Gábor B Brenner, Barnabás Váradi, Bence Ágg iD, Csenger Kovácsházi, Olivér M Balogh, Donagh Egan, Kieran Wynne, David Matallanas, Rainer Schulz, Péter Ferdinandy, Zoltán Giricz und 1 weitere

British Journal of Pharmacology · 2025

DOI: 10.1111/bph.70106 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Pharmacology, 2025. Verfasst von Bennet Y Weber und 12 weiteren Autor:innen. Beteiligte Einrichtung: Center for Pharmacology and Drug Research and Development, Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary. Hauptthemen laut MEDLINE: Lactones, Sulfones, Cardiotoxicity, Cyclooxygenase 2 Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 115 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Európai Szociális Alap, Nemzeti Kardióvaszkuláris Laboratórium, Nemzeti Kutatási, Fejlesztési és Innovaciós Alap.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose Hidden cardiotoxicity is defined as drug‐induced cardiotoxicity that becomes obvious only in the presence of comorbidities. However, the molecular mechanisms of hidden cardiotoxicity are not always known. Therefore, unbiased multi‐omics approaches could assist in revealing regulatory pathways. The most notable representative of hidden cardiotoxic drugs is the cyclooxygenase‐2‐inhibitor, rofecoxib. We previously reported increased mortality in rats because of proarrhythmic effects of rofecoxib in ischaemic hearts. Here, we aimed to identify molecular mechanisms of hidden cardiotoxicity exemplified by rofecoxib that present prior to comorbidities. Experimental Approach Rats were treated with rofecoxib or its vehicle for 4 weeks. RNA sequencing and proteomic datasets of heart samples were used for differential expression and pathway reconstruction analyses. Key Results In this model, mechanisms of hidden cardiotoxicity could not be revealed by transcriptomic analyses. However, mass‐spectrometry‐based proteomics showed conspicuous changes, revealing 132 proteins that were dysregulated in expression or on phosphorylation sites. Importantly, the phospho‐proteomics allowed us to identify two kinases that may mediate cardiotoxicity. Finally, pathway reconstruction maps a complex molecular machinery whose clustered proteins regulate processes involving cytoskeleton binding, mRNA processing, proteolysis, translation, citrate acid cycle and calcium ion signalling. Conclusion and Implications This is the first demonstration that multi‐omics characterisation can reveal underlying regulatory pathways of hidden cardiotoxicity. Importantly, our study shows that transcriptomics gives limited information on the hidden cardiotoxic effects of rofecoxib, which are mainly mediated by changes in posttranslational modifications and protein expression. These changes, among other mechanisms, may disturb the cardiac calcium handling, which could explain the fatal arrhythmias following ischaemia/reperfusion observed with rofecoxib.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LactonesSulfonesCardiotoxicityCyclooxygenase 2 InhibitorsAnimalsProteomicsRatsMaleRats, WistarMultiomics

Stichwörter der Autor:innen

COX‐2phospho‐proteomicsposttranscriptional regulationposttranslational modificationproteomicsrofecoxibtranscriptomics

Substanzen

rofecoxibLactonesSulfonesCyclooxygenase 2 Inhibitors

Autor:innen und Institutionen

  • Center for Pharmacology and Drug Research and Development, Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary.
  • HUN-REN-SU System Pharmacology Research Group, Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary.
  • Pharmahungary Group, Budapest, Hungary.
  • Systems Biology Ireland and School of Medicine, University College Dublin, Dublin, Ireland.
  • Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland.
  • Institute of Physiology, Justus-Liebig University, Gießen, Germany.

ORCID-Profile: Bence Ágg

Förderung

  • Európai Szociális Alap
  • Nemzeti Kardióvaszkuláris Laboratórium
  • Nemzeti Kutatási, Fejlesztési és Innovaciós Alap
  • Innovációs és Technológiai Minisztérium
  • Nemzeti Kutatási Fejlesztési és Innovációs Hivatal
  • European Union
  • National Research, Development and Innovation Fund
  • HUN-REN Hungarian Research Network

Zitieren

APA

Weber, B. Y., Brenner, G. B., Váradi, B., Ágg, B., Kovácsházi, C., Balogh, O. M., Egan, D., Wynne, K., Matallanas, D., Schulz, R., Ferdinandy, P., Giricz, Z., & Görbe, A. (2025). Assessment of the molecular mechanisms of drug‐induced hidden cardiotoxicity by a multi‐omics approach: The example of rofecoxib. British Journal of Pharmacology. https://doi.org/10.1111/bph.70106

Vancouver

Weber BY, Brenner GB, Váradi B, Ágg B, Kovácsházi C, Balogh OM, et al. Assessment of the molecular mechanisms of drug‐induced hidden cardiotoxicity by a multi‐omics approach: The example of rofecoxib. British Journal of Pharmacology. 2025. doi:10.1111/bph.70106

BibTeX
@article{Weber2025,
  author = {Weber, Bennet Y and Brenner, Gábor B and Váradi, Barnabás and Ágg, Bence and Kovácsházi, Csenger and Balogh, Olivér M and Egan, Donagh and Wynne, Kieran and Matallanas, David and Schulz, Rainer and Ferdinandy, Péter and Giricz, Zoltán and Görbe, Anikó},
  title = {Assessment of the molecular mechanisms of drug‐induced hidden cardiotoxicity by a multi‐omics approach: The example of rofecoxib},
  journal = {British Journal of Pharmacology},
  year = {2025},
  doi = {10.1111/bph.70106}
}
Kostenlos starten →